UOM

Guyana Innovation Group (GIG) Unveils Ambitious Vision: Guyana Innovation Village at the Heart of Silica City Masterplan

Retrieved on: 
Wednesday, November 22, 2023
UOM, School, Blockchain, University, Master Plan, OEC, Non-governmental organization, GIG, City, Artificial intelligence, COP, AI, Element, Development, Creative industries

President Irfaan Ali's vision for Silica City reflects his administration's commitment to the welfare and sustainable future of Guyana.

Key Points: 
  • President Irfaan Ali's vision for Silica City reflects his administration's commitment to the welfare and sustainable future of Guyana.
  • The Guyana Innovation Village has attracted interest from global corporations, eager to collaborate and invest in Guyana.
  • Bashar Rihani, Director of the DAR Group, expressed enthusiasm for supporting Silica City and the Guyana Innovation Group.
  • The Silica City Masterplan aims to set a new standard in sustainable urban planning, showcasing the collaborative spirit of Guyana, Guyana Innovation Group, and the University of Miami.

The University of Melbourne Collaborates with Cognizant to boost student engagement

Retrieved on: 
Monday, December 4, 2023
CTSH, Research, Cognizant, University, Kristen Anderson-Lopez, Student, Communication, University of Melbourne, Teaching, UOM, CDP, Nursing, Management, Marketing

TEANECK, N.J., Dec. 4, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it was selected by The University of Melbourne (UoM or the University), a leading international university with a tradition of excellence in teaching and research, to help implement the Tealium Customer Data Platform (CDP). The University of Melbourne is consistently ranked among the world's top universities. 

Key Points: 
  • The University of Melbourne is consistently ranked among the world's top universities.
  • The University of Melbourne awarded Cognizant the brief to support the creation of data-led and personalised experiences for students, staff and alumni as it looks to enhance meaningful constituent engagement.
  • Speaking to the collaboration, Kristen Anderson, Director at Cognizant leading marketing modernisation, highlighted the company's enthusiasm in working with The University of Melbourne.
  • And, through the implementation of Tealium CDP, we look forward to helping UoM improve engagement with students, alumni, and community."

The University of Melbourne Collaborates with Cognizant to boost student engagement

Retrieved on: 
Monday, December 4, 2023
CTSH, Research, Cognizant, University, Kristen Anderson-Lopez, Student, Communication, University of Melbourne, Teaching, UOM, CDP, Nursing, Management, Marketing

TEANECK, N.J., Dec. 4, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it was selected by The University of Melbourne (UoM or the University), a leading international university with a tradition of excellence in teaching and research, to help implement the Tealium Customer Data Platform (CDP). The University of Melbourne is consistently ranked among the world's top universities. 

Key Points: 
  • The University of Melbourne is consistently ranked among the world's top universities.
  • The University of Melbourne awarded Cognizant the brief to support the creation of data-led and personalised experiences for students, staff and alumni as it looks to enhance meaningful constituent engagement.
  • Speaking to the collaboration, Kristen Anderson, Director at Cognizant leading marketing modernisation, highlighted the company's enthusiasm in working with The University of Melbourne.
  • And, through the implementation of Tealium CDP, we look forward to helping UoM improve engagement with students, alumni, and community."

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Retrieved on: 
Friday, May 19, 2023
Kaufman, UNIPD, Prefrontal cortex, Cerebrospinal fluid, Plasma, Motion, Frasier, Protein, Thalamus, Acquisition, Patient, Atidarsagene autotemcel, Randomized controlled trial, The New England Journal of Medicine, Cell, Disease, IDUA, UOM, Enzyme replacement therapy, Phenotype, DSM-IV codes, Tissue, University, Hip, Gene, Orchard, GRN, Dementia, San Raffaele Hospital, Growth, HSC, Cognition, Natural history, Kyphosis, Biomarker, MPS, Șaeș, Frontotemporal dementia, Webcast, Mortality, Therapy, Central nervous system, Doctor of Philosophy, Speech, HSCT, CNS, EDT, Health, MRI, SGSH, Dysplasia, Society, FTD, Finnish heritage disease, Hippocampus, Medical imaging, Pharmaceutical industry, Vaccine, Medical device, Nursing, Dentistry

BOSTON and LONDON, May 19, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic and neurodegenerative disorders. The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

Key Points: 
  • The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
  • At baseline, most patients presented with severe joint range of motion impairment, severe acetabular (hip) dysplasia and varying degrees of dorso-lumbar kyphosis.
  • Treatment with OTL-203 was generally well tolerated and demonstrated extensive metabolic correction over four years after treatment.
  • Data from in vivo studies indicate effective GRN protein delivery to the CNS of knockout mice transplanted with gene-modified HSCs.

AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Health, Stem Cells, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, GMP, VCN, Gaucher's disease, Central nervous system, University, Gene, Clinical trial, Glycogen, MPS II, Skin, Glycogen storage disease type II, MPS, CNS, Hunter syndrome, Gaucher, AVRO, HSPC, Patient, Physician, Annual general meeting, Cell, CFO, American Society of Gene and Cell Therapy, HSC, Innovation, UOM, FDA, Enzyme replacement therapy, Syndrome, Research, Safety, Society, GI, Cystine, DSM-IV codes, MHRA, Pharmaceutical industry, Medical device, Cryptocurrency

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.
  • Plan to initiate Guard3, a global registrational Phase 2/3 trial for GD3, in the second half of 2023, subject to regulatory alignment.
  • AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.
  • Based on AVROBIO’s current operating plan, AVROBIO expects its cash and cash equivalents as of March 31, 2023, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.

With Innovation-driven Quality, Sustainable Development, Wuling Motors(00305.HK)Returns to Profitability in 2022

Retrieved on: 
Friday, March 31, 2023
Acceleration, UOM, Wuling Motors, Cabin, NEV, Intelligence, Research, BYD, Golf, Carbon, Recycling, History, Sulfur dioxide, Engine, Atkinson, Coal, GWM, Car, Foton, Hozon, Growth, Wuling, Ecology, R, Transport, L4, RMB, Automation, D, Renewable energy, Automotive industry, Rail transport, Chery

Amidst changes in its internal and external environments, Wuling Motors Holdings Limited (the "Company" or "Wuling Motors",Stock Code:00305.HK) has shown remarkable innovation in leading the way toward high-quality development.

Key Points: 
  • Amidst changes in its internal and external environments, Wuling Motors Holdings Limited (the "Company" or "Wuling Motors",Stock Code:00305.HK) has shown remarkable innovation in leading the way toward high-quality development.
  • Faced with innovation and change in the global automotive industry, Wuling Motors actively seeks breakthroughs to achieve high-quality development.
  • Overseas business is also an important area for Wuling Motors to accelerate its layout in 2022.
  • Regarding carbon emission reduction, Wuling Motors achieved a significant reduction in 2022 by using 4,447.64 MWh of clean photovoltaic energy.

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 23, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, GMP, Tissue, VCN, University of California, San Diego Performance-Based Skills Assessment, Gaucher's disease, Enteropathy, University, Safety, Health care, Food, CMC, Aes, Clinical trial, MPS II, Skin, Glycogen storage disease, Cerebrospinal fluid, MPS, CNS, IDS, Cystinosis, AVRO, ERT, HSPC, Patient, Physician, Risk, Medicines and Healthcare products Regulatory Agency, Liver, CSF, HSC, UOM, FDA, Syndrome, Enzyme replacement therapy, Lymphadenopathy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hunter syndrome, GI, Cystine, DSM-IV codes, MHRA, Disease, Pharmaceutical industry, Vaccine, Gaucher

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.

Key Points: 
  • (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
  • “2022 was a transformative year for AVROBIO, topped in December with a robust clinical and regulatory update for our Gaucher disease program.
  • Safety data to date from GD1 and GD3 patients indicate no adverse events (AEs) related to drug product.
  • No major chemistry, manufacturing and controls (CMC) changes are anticipated for AVROBIO’s plato® gene therapy platform as the company prepares to enter a registrational trial for GD3.

Proactive news headlines including West Wits Mining, Cobalt Blue Holdings, Pharmaxis and Pursuit Minerals

Retrieved on: 
Wednesday, December 14, 2022
Lithium, PMR, Hand, CLA, UOM, Lithium Triangle, Rubidium, Rare-earth element, Research, RAC, University, LNR, Rio Grande, Copper, PXS, Proactivity, DUN, IOCG, DFS, OTCQB, APS, Saindak Copper Gold Project, Sparkler, ASX, FGR, Cobalt, REE, Whale shark, MCB, OTC, C29, Iron ore, Mining, Management, Renewable energy

Click here

Key Points: 
  • Click here
    Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) has appointed experienced senior global pharma executive Dr Simon Green to the Board of Directors as an independent non-executive director.
  • Click here
    Tempest Minerals Ltd (ASX:TEM) has completed the 2022 drilling program at the Meleya Project, part of the company’s flagship Yalgoo Portfolio in Western Australia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected].

SPEY RESOURCES EXTRACTS 99.5% BATTERY GRADE LITHIUM CARBONATE USING EKOSOLVE™ PROCESS FROM OUR FLAGSHIP CANDELA II, INCAHUASI SALAR PROJECT

Retrieved on: 
Monday, October 31, 2022
CMV, Bachelor of Science, Canadian Securities Exchange, Water, Chemical engineering, Candela, Metal, Solution, ICP-OES, MAIG, CEO, FRA, SGS, National instrument, Lithium carbonate, NI, Company, University, MBM, GLOBE, Geology, Revelstoke, Intention, CSE, UOM, News, OTC, Lithium chloride, Lithium, Spey

Vancouver, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Spey Resources Corp. (CSE: SPEY) (OTC: SPEYF) (FRA: 2JS) ("Spey or the "Company") is pleased to provide further information regarding its recent extraction of 99.5% battery grade lithium carbonate using the Ekosolve process.

Key Points: 
  • Vancouver, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Spey Resources Corp. (CSE: SPEY) (OTC: SPEYF) (FRA: 2JS) ("Spey or the "Company") is pleased to provide further information regarding its recent extraction of 99.5% battery grade lithium carbonate using the Ekosolve process.
  • The purity of the lithium carbonate was set at 99.5% based on the sodium carbonate used to convert the chloride.
  • The lithium carbonate produced after the B1 sample of 200 litres was processed using the EkoSolve process was analysed using ICP-OES.
  • Spey Resources is a Canadian mineral exploration company which has an 80% interest in the Candela II lithium brine project located in the Incahuasi Salar, Salta Province, Argentina.

The University of Melbourne Pivots its Cloud Digital Strategy Through Partnership with Talend

Retrieved on: 
Tuesday, August 16, 2022
UOM, Multimedia, Corporate services, University, University of Melbourne, Data management, Software as a service, Compliance, CRM, COVID-19, Data analysis, Gaps, Region, Solution, Student, ERP, Medicine, Video game console, Software

SYDNEY, Aug. 16, 2022 /PRNewswire/ -- Talend, a global leader in data integration and management, today announced that the University of Melbourne (UoM) has selected Talend Data Fabric for its cloud data platform, helping the public-spirited institution respond to the changing needs of the business by moving and managing healthy data in cloud, hybrid, and multi-cloud environments.

Key Points: 
  • "Last year, The UoM's integration platform strategy was set to transition the university's current hybrid integration platform to a target-state cloud integration platform," said Daniel Buttigieg, Director, Enterprise Technology, Business Services, The University of Melbourne.
  • "The University of Melbourne is making the proper choice by focusing on its data to move into the post-pandemic world.
  • Earlier this year, The University of Melbourne joined the Talend University Alliance program, a higher education program that addresses the shortage of skilled data workers and the rising demand for data integration expertise.
  • Talend, a global leader in data integration and data management, is taking the work out of working with data.